The Australian Business Review | Orthocell leaps closer to FDA approval after pivotal nerve-repair product study success

Orthocell has been featured in The Australian Business Review, following today’s announcement that the US FDA 510(k) regulatory study of peripheral nerve-repair product Remplir meets all endpoints. The successful completion of the study is a key component of the Company’s 510(k) application, which remains on schedule for submission in December CY24. Here’s an excerpt: “ , , – . . “ – – ,” .” Click to read the article.